Heart failure & cardiomyopathies
Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy
Authors' conclusion
PIMSRA was associated with a reduction of myocardial septal thickness and improvement in functional status in patients with NOHCM. The absence of major adverse events is also encouraging, but larger studies with a control arm are needed to confirm long-term safety.
Study context
- Population
- Adult patients with drug-refractory non-obstructive hypertrophic cardiomyopathy (NOHCM) and severe septal hypertrophy (≥28 mm)enrolled between June 2017 and June 2023, median follow-up 15 months
- Participants
- 20 patients
- Exposure
- Before vs after percutaneous intramyocardial septal radiofrequency ablation (PIMSRA)
- PIMSRAn = 20
- Outcome
- Major adverse clinical events
- Follow-up
- Within 30 days after the procedure
Main finding
As reported in the abstract
- No major adverse clinical events occurred
Observational data: associations, not effects.
Further findings
| Outcome | Mean difference (mm) (95% CI) | |
|---|---|---|
| Maximum interventricular septal thicknessAfter PIMSRAvs before PIMSRADecreased from 31.3 mm to 17.4 mm | −13.9 (−15.92 to −11.88) | |
| −20−10010Difference, mm (linear scale) |
| Outcome | Mean difference (95% CI) | |
|---|---|---|
| KCCQ-12 scoreAfter PIMSRAvs before PIMSRAImproved from 65.6 to 84.4 | 18.78 (11.62–25.93) | |
| −2002040Difference (linear scale) |
Left atrial volume index and left ventricular mass index
- Decreased significantly
Global longitudinal strain and global radial strain
- Improvements observed, indicating possibly enhanced myocardial performance
Arrhythmias (atrial fibrillation, high-grade conduction block, non-sustained ventricular tachycardia) · during the follow-up
- No increased risk found
Original publication
Percutaneous intramyocardial septal radiofrequency ablation: a novel treatment for drug-refractory non-obstructive hypertrophic cardiomyopathy with severe septal hypertrophy. Heart. Published 7 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →